Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Dynamics and regulation of nuclear import and nuclear movements of HIV-1 complexes.

Burdick RC, Delviks-Frankenberry KA, Chen J, Janaka SK, Sastri J, Hu WS, Pathak VK.

PLoS Pathog. 2017 Aug 21;13(8):e1006570. doi: 10.1371/journal.ppat.1006570. eCollection 2017 Aug.


Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation.

Delviks-Frankenberry KA, Nikolaitchik OA, Burdick RC, Gorelick RJ, Keele BF, Hu WS, Pathak VK.

PLoS Pathog. 2016 May 17;12(5):e1005646. doi: 10.1371/journal.ppat.1005646. eCollection 2016 May.


Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Delviks-Frankenberry KA, Lengruber RB, Santos AF, Silveira JM, Soares MA, Kearney MF, Maldarelli F, Pathak VK.

Virology. 2013 Jan 20;435(2):433-41. doi: 10.1016/j.virol.2012.09.021. Epub 2012 Oct 13.


Lack of Detection of Xenotropic Murine Leukemia Virus-Related Virus in HIV-1 Lymphoma Patients.

Delviks-Frankenberry KA, Chaipan C, Bagni R, Wyvill K, Yarchoan R, Pathak VK.

Adv Virol. 2011;2011:797820. doi: 10.1155/2011/797820. Epub 2011 Sep 8.


Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples.

Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, Devere White RW, Del Prete GQ, Mellors JW, Lifson JD, Kewalramani VN, Pathak VK, Coffin JM, Le Grice SF.

Adv Virol. 2011;2011:272193. doi: 10.1155/2011/272193. Epub 2011 Nov 17.


Characterization, mapping, and distribution of the two XMRV parental proviruses.

Cingöz O, Paprotka T, Delviks-Frankenberry KA, Wildt S, Hu WS, Pathak VK, Coffin JM.

J Virol. 2012 Jan;86(1):328-38. doi: 10.1128/JVI.06022-11. Epub 2011 Oct 26.


Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.

Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.

Nucleic Acids Res. 2012 Jan;40(1):345-59. doi: 10.1093/nar/gkr694. Epub 2011 Sep 8.


Recombinant origin of the retrovirus XMRV.

Paprotka T, Delviks-Frankenberry KA, Cingöz O, Martinez A, Kung HJ, Tepper CG, Hu WS, Fivash MJ Jr, Coffin JM, Pathak VK.

Science. 2011 Jul 1;333(6038):97-101. doi: 10.1126/science.1205292. Epub 2011 May 31.


Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.

Lengruber RB, Delviks-Frankenberry KA, Nikolenko GN, Baumann J, Santos AF, Pathak VK, Soares MA.

J Antimicrob Chemother. 2011 Apr;66(4):702-8. doi: 10.1093/jac/dkr005. Epub 2011 Jan 26.


Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells.

Chaipan C, Dilley KA, Paprotka T, Delviks-Frankenberry KA, Venkatachari NJ, Hu WS, Pathak VK.

J Virol. 2011 May;85(10):4888-97. doi: 10.1128/JVI.00046-11. Epub 2011 Feb 16.


The "Connection" Between HIV Drug Resistance and RNase H.

Delviks-Frankenberry KA, Nikolenko GN, Pathak VK.

Viruses. 2010 Jul 1;2(7):1476-1503.


P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages.

Burdick R, Smith JL, Chaipan C, Friew Y, Chen J, Venkatachari NJ, Delviks-Frankenberry KA, Hu WS, Pathak VK.

J Virol. 2010 Oct;84(19):10241-53. doi: 10.1128/JVI.00585-10. Epub 2010 Jul 28.


Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

Paprotka T, Venkatachari NJ, Chaipan C, Burdick R, Delviks-Frankenberry KA, Hu WS, Pathak VK.

J Virol. 2010 Jun;84(11):5719-29. doi: 10.1128/JVI.00134-10. Epub 2010 Mar 24.


A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.

J Virol. 2010 May;84(10):5238-49. doi: 10.1128/JVI.01545-09. Epub 2010 Mar 10.


Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.

Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F, Hase S, Takebe Y, Pathak VK.

J Virol. 2009 Sep;83(17):8502-13. doi: 10.1128/JVI.00859-09. Epub 2009 Jun 24.


Real-time PCR analysis of HIV-1 replication post-entry events.

Mbisa JL, Delviks-Frankenberry KA, Thomas JA, Gorelick RJ, Pathak VK.

Methods Mol Biol. 2009;485:55-72. doi: 10.1007/978-1-59745-170-3_5.


HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision.

Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, Jere A, Pathak VK.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10943-8. doi: 10.1073/pnas.0804660105. Epub 2008 Jul 30.


Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.

Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK.

J Virol. 2007 Jul;81(13):6837-45. Epub 2007 Apr 11.


Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.

Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, Coffin JM, Pathak VK.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):317-22. Epub 2006 Dec 19.

Supplemental Content

Loading ...
Support Center